Article
The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report.
ESMO open - 1 Oct 2022
Hardenberg M C, Patel B, Matthews C, Califano R, Garcia Campelo R, Grohe C, Hong M H, Liu G, Lu S, de Marinis F, Pérol M, Soo R A, Stiles B M, Tiseo M, Tsuboi M
Abstract excerpt
BACKGROUND: Rates of disease recurrence and death following surgery remain high in early-stage non-small-cell lung cancer (NSCLC), despite adjuvant treatment and curative intent. Recently, osimertinib showed overwhelming evidence for disease-free survival (DFS), as demonstrated by an overall reduction in the risk of disease recurrence or death in the adjuvant setting of 80% versus control in the ADAURA study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.